Japanese pharmaceutical company Takeda inaugurated its first Innovation Capability Centre (ICC) in Bengaluru, marking its debut in Asia. The ICC aims to employ 750 professionals, including software ...

SAN FRANCISCO, Jan 16 (Reuters) - The pharmaceutical industry, grappling with new government limits on drug prices, is focusing its requests for president-elect Donald Trump and Congress on ...

Photo: Getty Leading pharmaceutical and IT companies have said they will quit Ireland if a proposed ban on so-called forever chemicals is introduced. Pfizer, Intel and other major employers are ...

As I step into Rajeev Juneja’s office at Mankind Pharma’s Delhi headquarters, the wall in front of me immediately commands attention. It features a collection of iconic quotes and striking ...

Pharmaceutical manufacturing encompasses all processes involved in the manufacturing and production of biological and medical products, botanical drugs, and herbs, as well as other pharmaceutical ...

The growing investment in India's CDMO sector indicates confidence in India’s pharmaceutical sector and its potential - A detailed analysis. With the U.S. increasingly adopting an anti-China ...

Our work is licensed under Creative Commons (CC BY-NC-ND 3.0). Feel free to republish and share widely.

Jan 11 (Reuters) - Gilead Sciences (GILD.O), opens new tab said on Saturday that it entered into a partnership with Denmark's LEO Pharma to develop programs to treat patients with inflammatory ...

Alliance Pharma has agreed to a £349.7 million pound takeover by DBAY Advisors, its biggest shareholder. The deal would see shareholders get 62.5p per share, representing a 41% uplift on Alliance ...

Typically, the election of a Republican to the White House is welcome news for the biotechnology and pharmaceutical sectors. The incoming administration is a more uncertain prospect, however.

Pharmaceutical stocks represent an interesting prospect — while it is incredibly tough to separate the wheat from the chaff, picking a winner early on is more or less a ticket to outsized returns.

In the final weeks of 2024, pharmaceutical companies struck a handful of deals with China-based biotechs, with antibody-drug conjugates high on the wish list. The flurry of activity reflects a ...